CRIS Current Research Information System

PEA, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 14.672
NA - Nord America 10.652
EU - Europa 9.681
SA - Sud America 1.238
AF - Africa 367
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 36.663
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.430
SG - Singapore 4.378
CN - Cina 3.716
IT - Italia 3.650
VN - Vietnam 2.996
DE - Germania 1.450
GB - Regno Unito 1.188
HK - Hong Kong 942
IN - India 893
BR - Brasile 885
SE - Svezia 710
KR - Corea 661
FR - Francia 578
NL - Olanda 483
RU - Federazione Russa 459
JP - Giappone 342
IE - Irlanda 291
FI - Finlandia 220
AR - Argentina 137
ID - Indonesia 122
CI - Costa d'Avorio 114
UA - Ucraina 103
ZA - Sudafrica 82
BD - Bangladesh 81
CA - Canada 78
ES - Italia 77
PH - Filippine 76
AT - Austria 74
CH - Svizzera 67
MX - Messico 67
PL - Polonia 66
IQ - Iraq 63
TR - Turchia 62
EC - Ecuador 59
TH - Thailandia 53
AU - Australia 43
TW - Taiwan 41
BG - Bulgaria 40
PK - Pakistan 40
SA - Arabia Saudita 40
PA - Panama 36
CO - Colombia 33
CL - Cile 32
SC - Seychelles 31
BE - Belgio 28
HR - Croazia 25
PY - Paraguay 25
JO - Giordania 24
PE - Perù 24
RO - Romania 23
VE - Venezuela 22
GR - Grecia 21
PT - Portogallo 21
UZ - Uzbekistan 21
EE - Estonia 19
EG - Egitto 17
MA - Marocco 17
NG - Nigeria 16
TN - Tunisia 15
CZ - Repubblica Ceca 14
IL - Israele 14
IR - Iran 13
MY - Malesia 13
KE - Kenya 12
TG - Togo 12
LT - Lituania 11
UY - Uruguay 11
AE - Emirati Arabi Uniti 10
HU - Ungheria 10
SK - Slovacchia (Repubblica Slovacca) 10
AZ - Azerbaigian 9
DO - Repubblica Dominicana 9
NP - Nepal 9
DZ - Algeria 8
LV - Lettonia 7
BO - Bolivia 6
CR - Costa Rica 6
CY - Cipro 6
ET - Etiopia 6
JM - Giamaica 6
LB - Libano 6
OM - Oman 6
RS - Serbia 6
UG - Uganda 6
GA - Gabon 5
DK - Danimarca 4
KG - Kirghizistan 4
MN - Mongolia 4
NO - Norvegia 4
QA - Qatar 4
AO - Angola 3
BH - Bahrain 3
BY - Bielorussia 3
CM - Camerun 3
FJ - Figi 3
KH - Cambogia 3
KZ - Kazakistan 3
LI - Liechtenstein 3
MD - Moldavia 3
ME - Montenegro 3
Totale 36.588
Salva come PNG Salva come JPEG
Città #
Singapore 2.996
Hefei 1.298
Ashburn 1.111
San Jose 1.109
Southend 952
Hong Kong 893
Fairfield 813
Ho Chi Minh City 734
Seoul 621
Dallas 580
Santa Clara 579
Hanoi 550
Bologna 494
Princeton 477
Woodbridge 411
Lauterbourg 388
Beijing 380
Milan 374
Boardman 359
Dong Ket 354
Seattle 345
Houston 333
Cambridge 300
Tokyo 291
Wilmington 289
Dublin 287
Rome 249
Chandler 245
Los Angeles 224
Ann Arbor 184
Des Moines 158
Council Bluffs 154
Redondo Beach 135
Bengaluru 132
New York 127
Helsinki 125
Da Nang 117
Abidjan 113
Buffalo 113
Redwood City 105
Chicago 101
Haiphong 96
São Paulo 86
Shanghai 82
Frankfurt am Main 76
Turin 73
Naples 72
Florence 70
Jakarta 70
Lappeenranta 66
Berlin 62
San Diego 62
Genoa 57
Nuremberg 56
Guangzhou 55
The Dalles 55
Amsterdam 52
Nanjing 52
Munich 51
Redmond 51
London 49
Castel Maggiore 48
Verona 45
Hangzhou 44
Tongling 44
Bremen 43
Jinan 42
Medford 41
Vienna 40
Modena 38
Mumbai 38
Paris 37
Warsaw 37
Bern 35
Sofia 35
Hải Dương 34
Biên Hòa 33
Can Tho 32
Phoenix 32
Baghdad 31
Istanbul 31
Bari 30
Padova 30
Falkenstein 28
Saint Petersburg 28
Trieste 28
Turku 28
Johannesburg 27
Orem 27
Vicenza 27
Xi'an 27
Yubileyny 27
Padua 26
Salt Lake City 26
Toronto 26
Wuhan 26
Zhengzhou 26
Changsha 25
Rio de Janeiro 25
Amman 23
Totale 22.163
Salva come PNG Salva come JPEG
Nome #
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: One stone for two birds? 1.173
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence 346
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 310
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients 308
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis 244
Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel 243
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 238
Impact of Continuous Infusion Meropenem PK/PD Target Attainment on C-Reactive Protein Dynamics in Critically Ill Patients With Documented Gram-Negative Hospital-Acquired or Ventilator-Associated Pneumonia 230
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 224
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach 213
[PK/PD profile and post-marketing surveillance of levofloxacin] 207
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 198
Is it Time to Move From Intermittent to Continuous Infusion Administration of Vancomycin? 196
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections 194
Enhancement of in-vitro activity of ofloxacin and gentamicin by rat serum 194
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections 193
Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales 192
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics 188
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 187
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 185
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 184
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 183
Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis 182
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use 179
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction 179
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 178
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams 177
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 175
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 172
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow 170
A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue 169
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 169
Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. 169
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 168
Acute wound infections management: the ‘Don’ts’ from a multidisciplinary expert panel 167
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 167
Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales 166
Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis 165
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 165
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 164
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 164
Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study 164
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run 162
Methicillin-resistant Staphylococcus epidermidis knee prosthetic infection treatment with two-stage revision and fosfomycin–rifampin combination therapy: a case report 161
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. 161
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 161
Population Pharmacokinetics and Pharmacodynamics of Dalbavancin and C-Reactive Protein in Patients with Staphylococcal Osteoarticular Infections 160
Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections? 159
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis 157
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 157
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections 157
Leveraging Neural ODEs for Population Pharmacokinetics of Dalbavancin in Sparse Clinical Data 157
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. 154
Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections 153
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 151
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 151
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid 148
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring 146
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol 146
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem 145
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 145
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 144
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae 144
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients 144
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 143
Could de-escalation of antibiotic therapy be feasible even for documented methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia? 143
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 142
The current role of glycopeptides in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts 142
A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) 142
Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia 140
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 140
Population Pharmacokinetic and Pharmacodynamic Analysis for Maximizing the Effectiveness of Ceftobiprole in the Treatment of Severe Methicillin-Resistant Staphylococcal Infections 139
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# 139
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings 139
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections 138
Blood concentrations and clinical effect of cyclosporin in psoriasis 137
Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia 134
Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice 134
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions 134
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 134
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients 133
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors 133
Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis 132
β-blockers and diltiazem combination—bear in mind the risk of heart block 132
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections 131
Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections 130
Liposome-encapsulated daunorubicin for PGP-related multidrug resistance 129
Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action 128
Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis 128
Liposome encapsulated daunorubicin (daunoxome) for acute leukemia 128
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6 127
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of bsis, cutis, and ciais caused by enterobacterales in critically ill adult patients 127
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases 126
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring 125
Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization 125
Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients 124
Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. 124
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective 124
What does it mean: Appropriate therapy for methicillin-resistant Staphylococcus aureus? [17] 124
Comparison of the antibacterial activity and synergistic activity towards antibiotics of different mammalian sera 124
Totale 17.376
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.209 0 0 0 0 0 0 0 0 0 382 52 775
2021/20223.502 126 51 221 215 623 321 112 289 327 163 460 594
2022/20232.836 354 309 161 431 155 184 173 157 489 92 180 151
2023/20242.003 99 171 129 207 178 204 204 180 135 207 160 129
2024/20257.972 275 1.026 744 590 991 404 690 246 170 756 655 1.425
2025/202616.853 1.339 2.328 2.140 1.682 1.373 843 2.207 994 3.020 927 0 0
Totale 37.537